A Double-blind, Randomized, Placebo-controlled Study to Assess the Safety and Efficacy of Nebulized PC945 When Added to Systemic Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis (OPERA-T Study)
Latest Information Update: 12 Jun 2025
At a glance
- Drugs Opelconazole (Primary) ; Antifungals
- Indications Invasive bronchopulmonary aspergillosis
- Focus Registrational; Therapeutic Use
- Acronyms OPERA-T
- Sponsors Pulmocide
Most Recent Events
- 17 Jan 2025 Planned End Date changed from 30 Dec 2025 to 30 Apr 2026.
- 17 Jan 2025 Planned primary completion date changed from 30 Nov 2025 to 30 Mar 2026.
- 22 Nov 2024 Planned End Date changed from 30 Apr 2025 to 30 Dec 2025.